Wegovy and heart health: Does the medicine reduce cardiovascular risk?

This one is not written for someone at the very start of thinking about weight loss.

It is written for people who already have a cardiac history. A heart attack a few years ago. A stroke. Leg pain when walking that turned out to be peripheral arterial disease.

You are probably already taking a statin, something for blood pressure, possibly an anticoagulant, and the last thing you want is another medicine you do not understand.

We get this question a lot: Is Wegovy a weight loss drug that also happens to be good for heart health?

This guide is designed to give you an honest answer with evidence-backed insights, so you know what you’re signing up for.

Before you begin: A little bit about OnlineClinic

OnlineClinic has been operating since 2011 and has treated more than 2.1 million patients.

The pharmacy is registered with the General Pharmaceutical Council (GPhC), our prescribers are registered with the General Medical Council (GMC), and the service is regulated by the Care Quality Commission (CQC).

As of August 2026, on Trustpilot, the service rating is 4.6 out of 5 based on 6,554 reviews.

If GLP-1 medicines are new to you, start with our complete UK guide to GLP-1 medications and come back to this one.

In the UK, the MHRA and NICE recommended, approved, and licensed semaglutide (the active ingredient in Wegovy) for cardiovascular health.

Here’s what that means.

The licence (MHRA, July 2024)

A licence is permission for a medicine to be sold and prescribed in the UK for a stated purpose.

On 23 July 2024, the MHRA approved Wegovy 2.4mg for reducing the risk of cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or above.

Before that date, Wegovy's UK licence covered weight management only.

The NICE recommendation (TA1152, 7 May 2026)

NICE assesses whether a licensed medicine represents good clinical value for a defined group of patients.

Wegovy is the first and so far the only GLP-1 receptor agonist that NICE has recommended specifically for reducing major adverse cardiovascular events.

Every regulatory decision described above rests on one large trial.

The SELECT trial enrolled 17,604 adults across 41 countries.

All participants were 45 or older, had a BMI of 27 or above, and had established cardiovascular disease, but no history of diabetes.

Half of these participants received Wegovy 2.4mg once weekly, and the other half received a placebo injection.

Both groups continued their usual cardiac care, including statins, blood pressure medicines, and antiplatelet treatment.

The trial ran for a little over three years.

This is the section most people skip to, so we have kept it precise. NICE sets out two conditions, and you need both.

Wegovy's UK dose ceiling rose to 7.2mg in early 2026, and a single-injection 7.2mg pen followed in April 2026.

Naturally enough, people assume more milligrams mean more heart protection.

The evidence does not currently support that assumption for a simple reason.

The SELECT trial tested 2.4mg. The licence and the NICE recommendation both describe semaglutide up to a maintenance dose of 2.4mg once weekly.

No cardiovascular outcomes trial has been run at 7.2mg.

So the two doses currently answer different questions.

If your priority is heart health, the 2.4mg dose is the evidence-based dose.

If your priority is maximum weight loss, and heart health is a secondary consideration, that changes the conversation.

Your prescriber will weigh both. The full dosage schedule is covered in Wegovy dosage schedule explained.

This turns out to be one of the more interesting questions, and the answer affects how the medicine gets used.

If the heart health benefit came purely from losing weight by taking Wegovy, then any method of losing the same amount of weight should deliver the same cardiac protection. The evidence so far suggests it is not that simple.

An analysis of the SELECT trial estimated that roughly 33% of the cardiovascular benefit could be explained by the reduction in waist circumference.

The remaining benefits may have come from improved blood pressure, inflammatory markers, and direct effects on blood vessels.

More recent studies reflect the same.

A study published in July 2026 followed patients with pre-existing cardiovascular disease who started semaglutide.

Later cardiovascular outcomes tracked more closely with the maximum dose a patient reached than with how much weight they actually lost.

Mounjaro produces greater average weight loss compared to Wegovy, so does it hold a licence for cardiovascular health as well?

Mounjaro now has cardiovascular outcome evidence of its own. The SURPASS-CVOT trial was published in December 2025.

It enrolled 13,165 adults who had both type 2 diabetes and cardiovascular disease, and it compared tirzepatide (Mounjaro’s active ingredient) against dulaglutide, an older GLP-1 medicine with proven cardiovascular benefit, over approximately four years.

The study found that major adverse cardiovascular events occurred in 12.2% of the tirzepatide group compared with 13.1% of the dulaglutide group.

Three differences matter when you set this next to the SELECT trial.

• The comparison was different. The SELECT trial compared Wegovy against a placebo. SURPASS-CVOT compared Mounjaro against an active medicine already known to help with heart health, which is a harder test to win and produces a smaller apparent gap
• The population was different. Everyone in the SURPASS-CVOT trial had type 2 diabetes. Nobody in the SELECT trial did
• The regulatory position is different. Mounjaro does not hold a UK licence for cardiovascular risk reduction, and NICE has not recommended it for that purpose

The update as of today: If cardiovascular risk reduction is the specific reason you are considering treatment, Wegovy is the one with the UK licence for it. For a fuller side-by-side on weight loss, dosing, and cost, see Mounjaro vs Wegovy.

Worth stating plainly, because the marketing noise around GLP-1 medicines has become considerable.

• It is not a heart failure treatment. Wegovy is not indicated to reduce heart failure events. Trials in obesity-related heart failure have shown improvements in symptoms and walking ability, and that research is genuinely promising, but it is not what the current UK licence covers
• It is not a treatment for peripheral arterial disease symptoms. The STRIDE trial published in The Lancet in 2025 found that semaglutide improved maximum walking distance in people with type 2 diabetes and symptomatic peripheral arterial disease, by around 13% against a placebo. That trial used a 1.0mg dose in a diabetes population, which is a different product and a different licence
• It is not a replacement for anything you already take. Every SELECT trial participant stayed on their standard cardiac care throughout

For most people in this group, the answer is reassuring. Very little changes, and nothing gets removed.

• Blood pressure tends to fall on Wegovy, partly through weight loss and partly independently. If you take antihypertensives (medicines to reduce blood pressure), this is worth monitoring, particularly if you get lightheaded when standing
• Heart rate tends to rise slightly with GLP-1 medicines, typically by a few beats per minute. It was not associated with harm in the SELECT trial, but mention it to your prescriber if you notice palpitations
• Oral medicines are absorbed more slowly because Wegovy slows stomach emptying. For most cardiac medicines, this makes no meaningful difference, though it is a reason for your prescriber to see your full medicine list
• Watch out for dehydration. Vomiting or diarrhoea in the early weeks, combined with diuretics (water pills) or certain blood pressure medicines, can affect kidney function. Drink properly and tell your prescriber if sickness lasts more than a day or two

The side effects, if you have a cardiac history, are the same as for anyone else on Wegovy. Most side effects are gastrointestinal, and are at their peak mostly in the first weeks, and they settle as the body adjusts.

The week-by-week timeline, and what usually helps at each stage, is in Wegovy side effects week by week.

Wegovy is not suitable if you:

• Are pregnant, planning a pregnancy, or breastfeeding
• Have a personal or family history of medullary thyroid carcinoma
• Have Multiple Endocrine Neoplasia syndrome type 2
• Have had a serious allergic reaction to semaglutide or any ingredient in the pen

Discuss carefully with a prescriber if you:

• Have had a cardiovascular event recently, particularly within the last few months
• Have heart failure, especially if your symptoms are unstable or you have been in the hospital for it recently
• Have a history of pancreatitis or gallbladder disease
• Have severe kidney or liver problems
• Have diabetic retinopathy
• Take insulin or a sulphonylurea
• Have a history of an eating disorder

Our process is straightforward. From start to finish, this is what happens when you order with us:

1. Fill in the medical questionnaire. It takes 5 to 10 minutes. For anyone with a cardiac history, answer the heart-related questions in full, including dates of events, procedures, and every current medicine. The questions are thorough on purpose
2. A GMC-registered prescriber reviews your answers. If they need more details or want confirmation from the clinician managing your heart, they will message you through your account
3. If treatment is approved, it is dispensed and dispatched. Next-day delivery, with needles, a sharps bin, and the full patient information leaflet included. Wegovy pens are stable below 30°C and ship in standard insulated packaging
4. If it is not approved, the prescriber explains why. You are not charged for treatment that is not issued

Our Wegovy prices start at £69.99, and every price includes the prescription, the consultation, the packaging, and delivery. There are no hidden fees.

We prescribe Wegovy for weight management following an online consultation.

Where you have a cardiac history, our prescribers will often want your GP or cardiology team involved, and may decline to issue treatment online if they judge that ongoing in-person monitoring is the safer route.